Neurocrine Biosciences' Huntington's disease drug gets FDA approval

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' (NBIX.O) INGREZZA drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday.